Blog

Everything you need to know about GLP-1 receptor agonists — how they work, what the clinical trials show, side effects, eligibility, and how to choose a provider.

The FDA ended the semaglutide shortage in February 2025, upending the compounded GLP-1 market. Here's what changed, what's legal, and how to choose.

From $25/month with a savings card to $1,350 list price — the GLP-1 pricing landscape is confusing. Here's every option with real numbers.

Starting a GLP-1? Here's a realistic week-by-week breakdown of what happens — from the initial consultation through your first dose escalation.

Medicare will begin covering GLP-1 weight loss medications at $50/month starting July 2026. Here's who qualifies, how it works, and what comes next.

Retatrutide achieved 28.7% weight loss in Phase 3 trials — nearly double semaglutide. Here's everything known about Eli Lilly's next-generation triple-agonist, from clinical data to expected approval timeline.

The FDA just approved Eli Lilly's Foundayo (orforglipron) — the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.

Beyond Wegovy and Zepbound, a new generation of obesity drugs is racing toward FDA approval. CagriSema, MariTide (monthly injection), survodutide, and more — here's every drug in the pipeline with clinical data.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.

The two most prescribed GLP-1 weight loss drugs go head to head — clinical results, pricing, side effects, insurance, and which one is right for you.